[go: up one dir, main page]

NZ515567A - Method for treating chronic pain using MEK inhibitors - Google Patents

Method for treating chronic pain using MEK inhibitors

Info

Publication number
NZ515567A
NZ515567A NZ515567A NZ51556700A NZ515567A NZ 515567 A NZ515567 A NZ 515567A NZ 515567 A NZ515567 A NZ 515567A NZ 51556700 A NZ51556700 A NZ 51556700A NZ 515567 A NZ515567 A NZ 515567A
Authority
NZ
New Zealand
Prior art keywords
chronic pain
treating chronic
mek inhibitors
formula
pain
Prior art date
Application number
NZ515567A
Inventor
Alistair Dixon
Kevin Lee
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ515567A publication Critical patent/NZ515567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)

Abstract

Described is the use of a MEK inhibitor of formula I, or formula I(A), for which the substituents are defined herein, in the manufacture of a medicament for the treatment of pain.
NZ515567A 1999-07-16 2000-07-05 Method for treating chronic pain using MEK inhibitors NZ515567A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16
PCT/US2000/018347 WO2001005392A2 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors

Publications (1)

Publication Number Publication Date
NZ515567A true NZ515567A (en) 2004-03-26

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515567A NZ515567A (en) 1999-07-16 2000-07-05 Method for treating chronic pain using MEK inhibitors

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230251B1 (en) 2000-07-19 2015-11-30 Warner-Lambert Co. Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
SI2275102T1 (en) 2002-03-13 2015-12-31 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP4896717B2 (en) 2003-07-24 2012-03-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー N-methyl-substituted benzamidazole
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004279721A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited Process for producing aminopyrrolidine derivative and intermediate compound
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
EP2251327B1 (en) 2003-11-19 2014-02-12 Array Biopharma, Inc. Heterocyclic inhibitors of mek
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
SI1934174T1 (en) 2005-10-07 2011-08-31 Exelixis Inc Azetidines as mek inhibitors for the treatment of proliferative diseases
ES2372955T3 (en) 2006-07-06 2012-01-30 Array Biopharma, Inc. CICLOPENTA [D] PYRIMIDINS AS INHIBITORS OF THE PROTEIN CINASA AKT.
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
TR201900306T4 (en) 2006-12-14 2019-02-21 Exelixis Inc Methods of using Mek inhibitors.
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP5542282B2 (en) 2007-07-05 2014-07-09 アレイ バイオファーマ、インコーポレイテッド Pyrimidylcyclopentane as an AKT protein kinase inhibitor
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (en) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
BRPI0821227A2 (en) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Compound, pharmaceutical composition, method for preparing same, use of a compound, method for treating a disease or disorder, for inhibiting raf function and for inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more more of them
JP5539225B2 (en) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Hydroxylated pyrimidylcyclopentane as an AKT protein kinase inhibitor
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5746630B2 (en) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted sulfonamidophenoxybenzamide
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
JP2013508320A (en) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト Substituted halophenoxybenzamide derivatives
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CN104945401B (en) 2010-02-01 2017-09-05 癌症研究技术有限公司 IP compounds and their applications in the treatment
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
WO2012135753A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and erlotinib, and methods of use
RU2013148817A (en) 2011-04-01 2015-05-10 Дженентек, Инк. COMBINATIONS OF ACT AND MEK INHIBITOR COMPOUNDS AND WAYS OF THEIR APPLICATION
BR112015008113B1 (en) 2012-10-12 2022-05-24 Exelixis, Inc. New process to prepare compounds for use in cancer treatment
CA2923835C (en) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US10040769B2 (en) 2015-10-27 2018-08-07 Regenacy Pharmaceuticals, Llc HDAC inhibitors for the treatment of diabetic peripheral neuropathy
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
EP3989957A1 (en) * 2019-06-28 2022-05-04 University of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
AU756586C (en) * 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en) * 1997-07-01 2004-12-15 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and pharmaceutical compositions comprising them for use as mek inhibitors
KR100609800B1 (en) * 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 How to treat arthritis with MEV inhibitor

Also Published As

Publication number Publication date
EP1202726A2 (en) 2002-05-08
CN1373660A (en) 2002-10-09
HUP0202623A3 (en) 2003-03-28
WO2001005392A2 (en) 2001-01-25
ZA200109907B (en) 2003-02-28
PE20010545A1 (en) 2001-06-04
JP2003504400A (en) 2003-02-04
PL352684A1 (en) 2003-09-08
TR200200082T2 (en) 2002-04-22
HUP0202623A2 (en) 2002-11-28
AU5786000A (en) 2001-02-05
CO5300398A1 (en) 2003-07-31
CA2374052A1 (en) 2001-01-25
KR20020012315A (en) 2002-02-15
WO2001005392A3 (en) 2001-07-19
AR024732A1 (en) 2002-10-23
IL147619A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
AU2483000A (en) Treatment of asthma with mek inhibitors
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
MXPA05006359A (en) Disease treatment via antimicrobial peptide inhibitors.
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
MY151032A (en) Treatment of tnf? related disorders
SE0104248D0 (en) Method of treatment
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
NZ517616A (en) Use of retigabin for treating neuropathic pain
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
MY137250A (en) Method of treatment of transplant rejection
TR200200204T2 (en) Treating chronic pain using MEK inhibitors.
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
TW200510397A (en) Conjugated complement cascade inhibitors
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
GB2396108B (en) Treatment of pain
IN2005KO00312A (en)
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
MXPA04011018A (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders.
AU2444399A (en) New use for pain management
MXPA05010800A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders.
NZ531109A (en) New mandelic acid derivatives and their use as thrombin inhibitors
NO20024545D0 (en) Procedures for treating congestive heart failure

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)